ABL112 / ABL Bio - LARVOL DELTA

A novel TIGIT and 4-1BB bispecific antibody, ABL112, exhibits potent in vitro and in vivo antitumor activity through dual immune modulation (AACR 2024) - "Additionally, combining ABL112 with pembrolizumab significantly inhibited tumor growth better than combining anti-TIGIT monoclonal antibody with pembrolizumab. In conclusion, ABL112 exhibited potent in vitro and in vivo anti-tumor activity through multiple mode of action including TIGIT inhibition and 4-1BB activation. These results strongly suggest that ABL112 is an innovative and promising therapeutic option with the combination of anti-PD-(L)1 therapies for cancer patients."

Bispecific • IO biomarker • Preclinical • Oncology • CD4 • CD8 • TIGIT

Fc-competent TIGITx4-1BB bispecific antibody exerts potent long-lasting antitumor activity by potentiating CD8+ T cell activity and Fcγ receptor-mediated modulation of the tumor microenvironment. (PubMed, J Immunother Cancer) - "Through multiple mechanisms of action, ABL112 exerted potent tumor-killing activity and immune memory response alone or in combination with anti-PD-(L)1 therapies, representing a promising new cancer treatment strategy."

Biomarker • IO biomarker • Journal • Oncology • CD8 • CXCL10 • CXCL11 • IFNG • PVR • TIGIT • TNFA

ABL Bio, ABL112 Research Paper Published in International Journal JITC [Google translation] (HIT News) - "ABL Bio...announced on the 4th that it published a research paper on the dual antibody immunotherapy cancer drug 'ABL112' in the international academic journal JITC (Journal for ImmunoTherapy of Cancer)....According to the research results, ABL112 restored T cell activity by blocking the interaction between TIGIT and CD155, and showed a sustained therapeutic effect compared to the TIGIT monoclonal antibody. In addition, high anticancer efficacy was confirmed not only as a monotherapy but also in combination therapy with a PD-(L)1 inhibitor."

Preclinical • Oncology